Global Cord Blood Corp
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation… Read more
Global Cord Blood Corp - Asset Resilience Ratio
Global Cord Blood Corp (CORBF) has an Asset Resilience Ratio of 78.05% as of March 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2022)
This chart shows how Global Cord Blood Corp's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Global Cord Blood Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $6.66 Billion | 78.05% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $6.66 Billion | 78.05% |
Asset Resilience Insights
- Very High Liquidity: Global Cord Blood Corp maintains exceptional liquid asset reserves at 78.05% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Global Cord Blood Corp Industry Peers by Asset Resilience Ratio
Compare Global Cord Blood Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
SMO ClinPlus Co. Ltd.
SHE:301257 |
Diagnostics & Research | 14.36% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Global Cord Blood Corp (2008–2022)
The table below shows the annual Asset Resilience Ratio data for Global Cord Blood Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-03-31 | 78.05% | $6.66 Billion | $8.53 Billion | +1.20pp |
| 2021-03-31 | 76.85% | $6.08 Billion | $7.91 Billion | +1.04pp |
| 2020-03-31 | 75.81% | $5.47 Billion | $7.22 Billion | -0.48pp |
| 2019-03-31 | 76.29% | $5.00 Billion | $6.55 Billion | +3.56pp |
| 2018-03-31 | 72.73% | $4.25 Billion | $5.84 Billion | +5.00pp |
| 2017-03-31 | 67.73% | $3.51 Billion | $5.18 Billion | -- |
| 2016-03-31 | 0.00% | $0.00 | $4.69 Billion | -- |
| 2015-03-31 | 0.19% | $7.71 Million | $4.12 Billion | +0.15pp |
| 2014-03-31 | 0.03% | $1.24 Million | $3.63 Billion | +0.01pp |
| 2012-03-31 | 0.02% | $354.00K | $1.82 Billion | -99.88pp |
| 2009-03-31 | 99.90% | $196.80 Million | $196.99 Million | +99.48pp |
| 2008-03-31 | 0.42% | $1.06 Million | $249.70 Million | -- |